Last reviewed · How we verify
Seizures associated with CDKL5 deficiency disorders — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ztalmy | GANAXOLONE | Marinus | Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC] | GABA A receptor alpha-2/beta-1/gamma-2 | 2022-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Marinus · 1 drug in Seizures associated with CDKL5 deficiency disorders
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Seizures associated with CDKL5 deficiency disorders:
- Seizures associated with CDKL5 deficiency disorders treatment updates — RSS
- Seizures associated with CDKL5 deficiency disorders treatment updates — Atom
- Seizures associated with CDKL5 deficiency disorders treatment updates — JSON
Cite this brief
Drug Landscape (2026). Seizures associated with CDKL5 deficiency disorders — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/seizures-associated-with-cdkl5-deficiency-disorders. Accessed 2026-06-10.
Related
- Seizures associated with CDKL5 deficiency disorders full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing